Author | Edward S. Kim, MD, FACP


New Targets and New Mechanisms in Lung Cancer

May 15, 2013

ByDaniel R. Carrizosa, MD, MS|Kathryn F. Mileham, MD, FACP|Daniel E. Haggstrom, MD|Gregory M. Brouse, MD|Raghava Induru, MD|Edward S. Kim, MD, FACP

This review will describe the well-known use of VEGF antibodies; the current uses of EGFR and ALK tyrosine kinase inhibitors; newer agents being used against MET, FGFR, and other intracellular targets; insights regarding the field of immunotherapy in lung cancer; and finally, newer developments in chemotherapy.

Bronchioloalveolar Carcinoma: a Translational Perspective

September 15, 2010

ByPierre Saintigny, MD, PhD|Ignacio I. Wistuba, MD|Edward S. Kim, MD, FACP

In this issue of Oncology, Levy and colleagues provide a comprehensive review of bronchioloalveolar carcinoma [BAC], with a focus on the management of this rare disease, which represents 4% of all lung cancers.[1] The definition of BAC was revised by the World Health Organization (WHO) in 2004, with changes made to the diagnostic criteria and classification.[2] BAC was defined as an adenocarcinoma of the lung that grows in a lepidic fashion along the alveolar septa without invasion of stroma, blood vessels, or pleura. BAC has been sub-classified into three types: nonmucinous, mucinous, and mixed.